Results 51 to 60 of about 8,986 (182)

Potent monoclonal antibodies against multidrug‐resistant hypervirulent Klebsiella pneumoniae

open access: yesInterdisciplinary Medicine, Volume 4, Issue 4, July 2026.
A novel immunization strategy using a low‐virulence, multidrug‐resistant strain yields synergistic monoclonal antibodies against hypervirulent Klebsiella pneumoniae. These antibodies provide cross‐serotype protection through a dual‐mechanism of pathogen clearance and immunomodulation, offering a promising non‐antibiotic therapeutic for resistant ...
Yushan Jiang   +10 more
wiley   +1 more source

Identification and Genomic Analysis of the First Salmonella typhimurium Monophasic Variant 1,4,[5],12:i:‐ Isolate Harbouring a Chromosomally Integrated blaNDM‐5

open access: yesMicrobial Biotechnology, Volume 19, Issue 7, July 2026.
This study reports the first clinical isolate of the monophasic variant of Salmonella typhimurium (serotype 1,4,[5],12:i:‐) ST34 harbouring a chromosomally integrated blaNDM‐5. The ~11 kb resistance region is flanked by two directly oriented IS26 elements, forming an IS26‐composite transposon.
Shihan Zeng   +4 more
wiley   +1 more source

In Vitro Activities of Ceftazidime-Avibactam and Comparator Agents Against Carbapenem-resistant Enterobacterales (CRE) Collected in Africa/Middle East ATLAS Global Surveillance Program 2018-2022

open access: yesInternational Journal of Infectious Diseases
Introduction: Avibactam (AVI) is a non-β-lactam β-lactamase inhibitor that when combined with the β-lactam ceftazidime (CAZ) has demonstrated activity against Class A, Class C and some Class D enzymes.
Dr Meredith Hackel   +2 more
doaj   +1 more source

Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa [PDF]

open access: yesAntimicrobial Agents and Chemotherapy, 2018
Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2,000/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the FDA, CLSI, and EUCAST as susceptible ...
Wright W. Nichols   +9 more
openaire   +2 more sources

Antibiotic‐Impregnated Calcium Sulfate Beads for Local Therapy of Severe Skull Base Osteomyelitis

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
Novel Local Therapy of Severe Skull Base Osteomyelitis. ABSTRACT We report on a patient with severe progressive osteomyelitis of the lateral skull base, despite targeted long‐term antibiotic therapy. Successful treatment and recovery of the facial nerve palsy were achieved through additional surgical debridement and insertion of synthetic calcium ...
Stefan Lyutenski   +3 more
wiley   +1 more source

Emergence of Fosfomycin Resistance Among ESBL‐Producing Escherichia coli in Abadan, Southwestern Iran

open access: yesHealth Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aim Escherichia coli is a key pathogen responsible for various infections, such as urinary tract infections, gastroenteritis, and wound infections. The increasing occurrence of antimicrobial resistance, particularly in extended‐spectrum β‐lactamase (ESBL)‐producing strains, poses a significant global health threat.
Nabi Jomehzadeh, Ali Fakari
wiley   +1 more source

The Role of Pharmacovigilance Database in Identifying Antibiotic Resistance and Inappropriate Use: An Analysis of VigiBase Reports From Lower‐Middle‐Income Countries

open access: yesPharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Background Digital databases such as pharmacovigilance (PV) databases could provide unique opportunities to monitor trends in suspected antibiotic resistance, ineffectiveness, and misuse, extending beyond their traditional role of tracking adverse drug reactions (ADRs).
Hager Saleh   +3 more
wiley   +1 more source

Antibiotic Susceptibility of Aerobic and Facultative Anaerobic Gram-Negative Rods in Hong Kong and Implications on Usefulness of Ceftazidime-Avibactam and Ceftolozane-Tazobactam

open access: yesAntibiotics
Due to the increasing resistance of aerobic and facultative anaerobic Gram-negative rods, ceftazidime-avibactam and ceftolozane-tazobactam have been launched in the market in the last few years.
Jade L. L. Teng   +9 more
doaj   +1 more source

Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria

open access: yesФармакоэкономика, 2019
Aim: to assess the economic outcomes of using ceftazidime + avibactam (compared with the recommended treatments) in adult patients with sepsis caused by carbapenem-resistant enterobacteria.Methods.
S. V. Nedogoda   +3 more
doaj   +1 more source

Guidelines for Essential Trauma Care: Second Edition (2026)

open access: yesWorld Journal of Surgery, Volume 50, Issue 6, Page 1409-1450, June 2026.
Injury is a major cause of death and disability globally, with the highest burden in low‐ and middle‐income countries (LMICs). Strengthening the organization and planning for trauma care (care of the injured) can improve care and lower mortality. In 2004, the International Association for Trauma Surgery and Intensive Care (IATSIC) and the World Health ...
Charles Mock   +41 more
wiley   +1 more source

Home - About - Disclaimer - Privacy